The phrase "a functioning graft" is correct and usable in written English.
It can be used in medical or biological contexts to refer to a graft that is successfully integrating and performing its intended function.
Example: "The surgeon was pleased to see that the patient had a functioning graft after the transplant procedure."
Alternatives: "an operational graft" or "a viable graft".
The major causes of graft loss after the first year are, first, chronic allograft nephropathy (CAN), and, second, death with a functioning graft.
This study protocol describes a prospective interventional clinical trial with the goal of demonstrating improved medication safety and CVD risk factor control in adult solitary kidney transplant recipients at least one-year post-transplant with a functioning graft.
From 14 top enrolling centers, 128 of 175 patients identified with a functioning graft at 2 years consented to enroll in an observational, noninterventional extension study to collect retrospectively and prospectively annual follow-up data for the interval since baseline (completion of the parent STN study at 24 months posttransplant).
post-transplant, and have a functioning graft.
Overall graft loss (including death with a functioning graft) was reported in all trials.
Patient deaths with a functioning graft were censored for the graft survival analysis.
We retrospectively analyzed 579 adult patients who received a first kidney (n = 498) or a kidney-pancreas (n = 81) transplant between 2007 and 2012, with a functioning kidney graft for at least 6 months, and in whom a CDC PRA test and anti-HLA antibodies screening had been performed before transplant.
During the 2nd year of follow-up, a total of three deaths with functioning graft occurred and five grafts failed.
Kidney-graft survival has improved since the introduction of the immunosuppressive agent cyclosporine (also called cyclosporin A; see below), and many centres have achieved a one-year survival rate of 80 percent and a two-year rate of 70 percent for patients with a functioning kidney graft from an unrelated cadaver donor.
All patients are alive with a functioning kidney graft at 27-39 mofths of follow-up.
A functioning arterial graft to the right coronary artery (RCA) is especially troublesome in terms of myocardial protection to the right ventricular (RV) muscle, whereas the conventional antegrade and retrograde cardioplegia infusion might provide enough protection to the left ventricle (LV).
